Trial
NCT03578432
Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy
Early Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Arizona
Collaborators
National Cancer Institute (NCI)
Condition
Salivary Gland Dysfunction
Intervention
Everolimus
Why stopped
UACC-PHX is no longer able to support the study and Novartis is unable to provide drug beyond December 2019.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-12-02